233 related articles for article (PubMed ID: 22951415)
1. Effect of BAX499 aptamer on tissue factor pathway inhibitor function and thrombin generation in models of hemophilia.
Gissel M; Orfeo T; Foley JH; Butenas S
Thromb Res; 2012 Dec; 130(6):948-55. PubMed ID: 22951415
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of tissue factor pathway inhibitor by the aptamer BAX499 improves clotting of hemophilic blood and plasma.
Gorczyca ME; Nair SC; Jilma B; Priya S; Male C; Reitter S; Knoebl P; Gilbert JC; Schaub RG; Dockal M; McGinness KE; Pabinger I; Srivastava A
J Thromb Haemost; 2012 Aug; 10(8):1581-90. PubMed ID: 22632032
[TBL] [Abstract][Full Text] [Related]
3. Improvement of spatial fibrin formation by the anti-TFPI aptamer BAX499: changing clot size by targeting extrinsic pathway initiation.
Parunov LA; Fadeeva OA; Balandina AN; Soshitova NP; Kopylov KG; Kumskova MA; Gilbert JC; Schaub RG; McGinness KE; Ataullakhanov FI; Panteleev MA
J Thromb Haemost; 2011 Sep; 9(9):1825-34. PubMed ID: 21696535
[TBL] [Abstract][Full Text] [Related]
4. Studies on the mechanism of action of the aptamer BAX499, an inhibitor of tissue factor pathway inhibitor.
Chang JY; Chantrathammachart P; Monroe DM; Key NS
Thromb Res; 2012 Sep; 130(3):e151-7. PubMed ID: 22658294
[TBL] [Abstract][Full Text] [Related]
5. Drug-drug interaction of the anti-TFPI aptamer BAX499 and factor VIII: studies of spatial dynamics of fibrin clot formation in hemophilia A.
Parunov LA; Soshitova NP; Fadeeva OA; Balandina AN; Kopylov KG; Kumskova MA; Gilbert JC; Schaub RG; McGinness KE; Ataullakhanov FI; Panteleev MA
Thromb Res; 2014 Jan; 133(1):112-9. PubMed ID: 24263002
[TBL] [Abstract][Full Text] [Related]
6. Aptamer ARC19499 mediates a procoagulant hemostatic effect by inhibiting tissue factor pathway inhibitor.
Waters EK; Genga RM; Schwartz MC; Nelson JA; Schaub RG; Olson KA; Kurz JC; McGinness KE
Blood; 2011 May; 117(20):5514-22. PubMed ID: 21389323
[TBL] [Abstract][Full Text] [Related]
7. Factor Xa and VIIa inhibition by tissue factor pathway inhibitor is prevented by a monoclonal antibody to its Kunitz-1 domain.
Augustsson C; Svensson A; Kjaer B; Chao TY; Wenjuan X; Krogh BO; Breinholt J; Clausen JT; Hilden I; Petersen HH; Petersen LC
J Thromb Haemost; 2018 May; 16(5):893-904. PubMed ID: 29532595
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of Tissue Factor Pathway Inhibitor (TFPI) as a Treatment for Haemophilia: Rationale with Focus on Concizumab.
Chowdary P
Drugs; 2018 Jun; 78(9):881-890. PubMed ID: 29845491
[TBL] [Abstract][Full Text] [Related]
9. Hemostatic properties of a TFPI antibody.
Petersen LC
Thromb Res; 2012 May; 129 Suppl 2():S44-5. PubMed ID: 22405586
[TBL] [Abstract][Full Text] [Related]
10. Hemostatic effect of a monoclonal antibody mAb 2021 blocking the interaction between FXa and TFPI in a rabbit hemophilia model.
Hilden I; Lauritzen B; Sørensen BB; Clausen JT; Jespersgaard C; Krogh BO; Bowler AN; Breinholt J; Gruhler A; Svensson LA; Petersen HH; Petersen LC; Balling KW; Hansen L; Hermit MB; Egebjerg T; Friederichsen B; Ezban M; Bjørn SE
Blood; 2012 Jun; 119(24):5871-8. PubMed ID: 22563084
[TBL] [Abstract][Full Text] [Related]
11. Aptamer BAX 499 mediates inhibition of tissue factor pathway inhibitor via interaction with multiple domains of the protein.
Waters EK; Genga RM; Thomson HA; Kurz JC; Schaub RG; Scheiflinger F; McGinness KE
J Thromb Haemost; 2013 Jun; 11(6):1137-45. PubMed ID: 23528042
[TBL] [Abstract][Full Text] [Related]
12. Small peptides blocking inhibition of factor Xa and tissue factor-factor VIIa by tissue factor pathway inhibitor (TFPI).
Dockal M; Hartmann R; Fries M; Thomassen MC; Heinzmann A; Ehrlich H; Rosing J; Osterkamp F; Polakowski T; Reineke U; Griessner A; Brandstetter H; Scheiflinger F
J Biol Chem; 2014 Jan; 289(3):1732-41. PubMed ID: 24275667
[TBL] [Abstract][Full Text] [Related]
13. Anti-tissue factor pathway inhibitor (TFPI) therapy: a novel approach to the treatment of haemophilia.
Chowdary P
Int J Hematol; 2020 Jan; 111(1):42-50. PubMed ID: 30302740
[TBL] [Abstract][Full Text] [Related]
14. The impact of tissue factor pathway inhibitor on coagulation kinetics determined by thrombelastography.
Audu P; Nielsen VG; Armstead V; Powell G; Kim J; Kim L; Mehta M
Anesth Analg; 2006 Oct; 103(4):841-5. PubMed ID: 17000790
[TBL] [Abstract][Full Text] [Related]
15. Activated factor X and thrombin formation triggered by tissue factor on endothelial cell matrix in a flow model: effect of the tissue factor pathway inhibitor.
van 't Veer C; Hackeng TM; Delahaye C; Sixma JJ; Bouma BN
Blood; 1994 Aug; 84(4):1132-42. PubMed ID: 8049429
[TBL] [Abstract][Full Text] [Related]
16. Tissue factor-independent inhibition of thrombin generation by tissue factor pathway inhibitor-α.
Thomassen MC; Heinzmann AC; Herfs L; Hartmann R; Dockal M; Scheiflinger F; Hackeng TM; Rosing J
J Thromb Haemost; 2015 Jan; 13(1):92-100. PubMed ID: 25348176
[TBL] [Abstract][Full Text] [Related]
17. Regulation of coagulation by tissue factor pathway inhibitor: Implications for hemophilia therapy.
Mast AE; Ruf W
J Thromb Haemost; 2022 Jun; 20(6):1290-1300. PubMed ID: 35279938
[TBL] [Abstract][Full Text] [Related]
18. Targeting TFPI for hemophilia treatment.
Peterson JA; Maroney SA; Mast AE
Thromb Res; 2016 May; 141 Suppl 2(Suppl 2):S28-30. PubMed ID: 27207418
[TBL] [Abstract][Full Text] [Related]
19. Mechanism of factor VIIa-dependent coagulation in hemophilia blood.
Butenas S; Brummel KE; Branda RF; Paradis SG; Mann KG
Blood; 2002 Feb; 99(3):923-30. PubMed ID: 11806995
[TBL] [Abstract][Full Text] [Related]
20. Regulation of tissue factor initiated thrombin generation by the stoichiometric inhibitors tissue factor pathway inhibitor, antithrombin-III, and heparin cofactor-II.
van 't Veer C; Mann KG
J Biol Chem; 1997 Feb; 272(7):4367-77. PubMed ID: 9020158
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
